Nirsevimab (Beyfortus) for Prevention of Severe RSV Disease in Young Children
Nirsevimab (Beyfortus) for Prevention of Severe RSV Disease in Young Children
September 18, 2023 (Issue: 1685)
The FDA has approved nirsevimab-alip (Beyfortus –
AstraZeneca/Sanofi), a long-acting monoclonal
antibody, for the prevention of respiratory syncytial
virus (RSV) lower respiratory tract disease in
neonates and infants born during or entering...more
- CDC. RSV surveillance & research. July 17, 2023. Available at: www.cdc.gov/rsv/research/index.html. Accessed August 29, 2023.
- C Rosas-Salazar et al. Respiratory syncytial virus infection during infancy and asthma during childhood in the USA (INSPIRE): a population-based, prospective birth cohort study. Lancet 2023; 401:1669. doi:10.1016/s0140-6736(23)00811-5
- S Hamid et al. Seasonality of respiratory syncytial virus ― United States, 2017-2023. MMWR Morb Mortal Wkly Rep 2023; 72:355. doi:10.15585/mmwr.mm7214a1
- MT Caserta et al. Palivizumab prophylaxis in infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics 2023; 152:e2023061803. doi:10.1542/peds.2023-061803
- B Kampmann et al. Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants. N Engl J Med 2023; 388:1451. doi:10.1056/nejmoa2216480
- MP Griffin et al. Single-dose nirsevimab for prevention of RSV in preterm infants. N Engl J Med 2020; 383:415. doi:10.1056/nejmoa1913556
- LL Hammitt et al. Nirsevimab for prevention of RSV in healthy late-preterm and term infants. N Engl J Med 2022; 386:837. doi:10.1056/nejmoa2110275
- WJ Muller et al. Nirsevimab for prevention of RSV in term and late-preterm infants. N Engl J Med 2023; 388:1533. doi: 10.1056/nejmc2214773
- J Domachowske et al. Safety of nirsevimab for RSV in infants with heart or lung disease or prematurity. N Engl J Med 2022; 386:892. doi:10.1056/nejmc2112186
- S Drysdale et al. Efficacy of nirsevimab against RSV lower respiratory tract infection hospitalization in infants: preliminary data from the HARMONIE phase 3b trial. 41st Annual Meeting of the European Society for Paediatric Infectious Diseases; Lisbon & online; May 8-12, 2023. Abstract 1178. Available at: https://bit.ly/3YEyjjk. Accessed August 29, 2023.
- FDA Briefing Document. Nirsevimab. Antimicrobial Drugs Advisory Committee Meeting, June 8, 2023. Available at: https://www.fda.gov/media/169226/download. Accessed August 29, 2023.
- JM Jones et al. Use of nirsevimab for the prevention of respiratory syncytial virus disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices — United States, 2023. MMWR Morbid Mortal Wkly Rep 2023; 72:920. doi:10.15585/mmwr.mm7234a4
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: Nirsevimab (Beyfortus) for Prevention of Severe RSV Disease in Young Children
Article code: 1685a
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
